Additionally, CDK4/6is has demonstrated remarkable clinical effects in neoadjuvant endocrine therapy and early breast cancer, as evidence continues to grow and the therapeutic range of CDK4/6 inhibitors continues to broaden. This evidence concerns the gene CDK4 and breast carcinoma.